Instability of Immunophenotype in Plasma Cell Myeloma
|
|
- Egbert Craig
- 5 years ago
- Views:
Transcription
1 Hematopathology / Instability of Immunophenotype in PCM Instability of Immunophenotype in Plasma Cell Myeloma Wenqing Cao, MD, 1 Charles L. Goolsby, PhD, 1 Beverly P. Nelson, MD, 1 Seema Singhal, MD, 2 Jayesh Mehta, MD, 2 and LoAnn C. Peterson, MD 1 Key Words: Plasma cell myeloma; Immunophenotype; Flow cytometry; Stability DOI: /8UVF7YQ1D4D4ETQV Abstract Little information has been reported describing antigen stability in plasma cell myeloma. In this study, the expression frequency and stability of 2 potential therapeutic targets, CD20 and CD52, along with the frequently aberrantly expressed CD56 antigen, were evaluated by flow cytometric analyses in 56 patients with plasma cell myeloma. Of the 56 patients, 23 (41%) showed immunophenotype change, including CD56 in 6 cases, CD20 in 7 cases, and CD52 in 17 cases. Combined CD56/CD52 change was seen in 3 cases and combined CD20/CD52 in 4 cases. No correlation was found between immunophenotype change and age, sex, stage, plasma cell morphologic features, extent of marrow involvement, time between analyses, type of therapy, or response to therapy. Immunophenotype shift was more common in patients with IgA than in patients with IgG paraprotein. Recognition of lack of stability in immunophenotype may be important, especially in antigen-directed treatment decisions and when specific phenotypes are used to detect residual disease. Plasma cell myeloma (PCM) is a neoplasm characterized by proliferation of a single clone of plasma cells, a monoclonal immunoglobulin, and skeletal destruction. 1 Multiparametric immunophenotyping of PCM by flow cytometry has been incorporated into practice in many laboratories, not only for diagnosis, but also for monitoring residual disease. 2,3 CD138+, CD38+, and dim CD45 to CD45 staining is common to normal and abnormal plasma cells. 4,5 Pan B-cell antigens such as CD19 and CD20 are negative in the majority of normal plasma cells and PCM cases. However, dim expression of CD19 and CD20 can be seen in normal plasma cells, and such expression may also be present in some cases of PCM. 3,5-7 Therefore, these antigens are not helpful in differentiating normal from abnormal plasma cells. Abnormal plasma cells are often identified by flow cytometric analyses based on the presence of monotypic cytoplasmic immunoglobulin light chain and, in a subset of cases, CD56 expression, which only rarely occurs in normal plasma cells. 4,5,8,9 Although flow cytometry is useful to identify abnormal plasma cells, the diagnosis of PCM requires correlation of other laboratory data, clinical findings, and radiologic results. PCM is currently an incurable disease, although agents such as thalidomide (Thalomid), lenalidomide (Revlimid), and bortezomib (Velcade) have provided effective salvage therapy for end-stage myeloma. 10 Increasing knowledge of tumor biology and immunology has led to the development of immunotherapeutic and immunoregulatory drugs. 11,12 Many clinical flow cytometry laboratories now assess expression of a number of potential therapeutically relevant targets, or markers (CD20, CD22, CD25, CD52, and 926 Am J Clin Pathol 2008;129: DOI: /8UVF7YQ1D4D4ETQV
2 Hematopathology / Original Article CD30), on the neoplastic cells of lymphoid and plasma cell malignancies. 2 Knowledge of the expression pattern of these potential therapeutic markers at the time of the diagnosis may allow for initiation of antigen/ligand-directed therapy at diagnosis or at relapse without reanalysis of tumor cells. Studies have suggested the possible role of such monoclonal antibody therapies directed against CD20 and CD52 in the subset of PCMs that are positive for these antigens. Clinical trials evaluating the efficacy of rituximab (anti-cd20 monoclonal antibody) in PCM have shown effectiveness in some cases that are CD ,14 Although more frequently used in relapsed or refractory chronic lymphocytic leukemia, alemtuzumab (anti-cd52 monoclonal antibody) is also a potential therapeutic target in PCM. 16 Studies have demonstrated heterogeneous CD52 expression in PCM. 9,17 In addition, alemtuzumab has been shown to exhibit antitumor activity in animals with early-stage PCM. 18 Many studies have examined the immunoprofile of PCM. 3-5,9 However, these studies have primarily focused on diagnostic utility and minimal residual disease monitoring with little information on immunophenotype stability of myeloma cells in individual patients or on stability of potential therapeutic targets. 7,19 The purpose of this study was to evaluate the expression frequency and stability of 2 potential therapeutic targets, CD20 and CD52, along with the frequently aberrantly expressed CD56 antigen. Materials and Methods Patients All patients had a diagnosis of PCM and were followed up at Northwestern Memorial Hospital, Chicago, IL, from January 2003 through August The diagnosis of PCM was established according to published World Health Organization criteria and staged by the Durie-Salmon system. 20 For the study, 320 flow cytometric analyses of bone marrow aspirates from patients with PCM were reviewed. In this series, 56 patients had at least 2 flow cytometric results with monotypic plasma cells present. The clinical data for each patient were reviewed, including age, sex, stage, M component, type of therapy (chemotherapy and/or stem cell transplantation), and response to therapy. Flow Cytometric Immunophenotyping Flow cytometric immunophenotypic studies were performed on bone marrow aspirates using 3- and 4-color flow cytometric analyses from January 2003 to August 2005, and 6-color analyses after August The monoclonal antibody combinations for the 3- and 4-color analyses were cytoplasmic κ/cytoplasmic λ/cd45/cd38, CD38/ CD56/CD45/CD138, and CD20/CD25/CD45/CD38 corresponding to the fluorochromes fluorescein isothiocyanate (FITC)/phycoerythrin (PE)/PE-Texas red/pe-cyanin 5 (PE-Cy5); and CD52/CD45/CD38 corresponding to the fluorochromes FITC/PE/PE-Cy5. The antibody combinations for 6-color analysis were cytoplasmic κ/cytoplasmic λ/cd138/cd56/cd38/cd45 and CD52/CD25/CD3/CD20/ CD38/CD45 corresponding to the fluorochromes FITC/ PE/peridinin chlorophyll protein (PerCP)-Cy5.5/PE-Cy7/ allophycocyanin (APC)/APC-Cy7. All antibodies for the 3- and 4-color analyses were purchased from Beckman Coulter (Fullerton, CA) except CD52, which was purchased from Invitrogen (Carlsbad, CA); for 6-color analyses, CD20 was from Beckman Coulter, CD52 from Invitrogen, and all others were from Becton Dickinson (San Jose, CA). Briefly, bone marrow aspirate samples were prepared for flow cytometric analysis as follows. For tubes assessing only surface antigens, an aliquot of bone marrow aspirate containing 1 to cells was processed using a modified Qprep (Beckman Coulter) procedure described earlier, 21 in which the fixative step was replaced by phosphate-buffered saline (PBS) containing sodium azide. Cells were then washed in PBS and resuspended in 100 µl of PBS/30% fetal bovine serum containing the recommended, or appropriately titered, amount of antibody, incubated for 15 minutes at room temperature (RT), washed in PBS, and resuspended in PBS/0.5% formaldehyde. For tubes assessing surface and cytoplasmic antigens, an aliquot of bone marrow aspirate sample containing 1 to cells was processed using 2 ml of ammonium chloride solution 9 for 10 minutes at RT on a rocker followed by 2 washes in PBS with resuspension in 100 µl of PBS/30% fetal bovine serum containing the recommended, or appropriately titered, amount of surface antigen directed antibody and incubated for 15 minutes at RT and washed. Cells were resuspended in 500 µl of PermiFlow fixation/permeabilization reagent (Invirion, Traverse City, MI) and incubated for 40 minutes at RT in the dark. The cell suspension was then washed in PBS and resuspended in 100 µl of PBS/50% normal mouse serum containing the anti-κ and anti-λ antibodies and incubated in the dark for 15 minutes at RT. Cells were then washed and resuspended in PBS for analysis. Flow Cytometric Data Analysis The 4-color flow cytometric data analysis was performed on a Beckman Coulter EPICS ALTRA flow cytometer and 6-color flow cytometric analysis on an LSRII (Becton Dickinson) flow cytometer. At the 4-color to 6-color analysis transition, a large series cross-comparison study was performed using specimens from healthy people and from patients with different diagnoses to validate the comparability Am J Clin Pathol 2008;129: DOI: /8UVF7YQ1D4D4ETQV 927
3 Cao et al / Instability o f Im m u n o p h e n o t y p e in PCM of the 2 approaches (data not shown). Abnormal plasma cells were selected based on CD38+, CD138+, and dim CD45+ to CD 45 staining and on monotypic cytoplasmic κ or λ immunoglobulin light chain staining zimage 1z. CD56, CD20, and CD52 were analyzed on gated cells containing more than 99% monotypic plasma cells. A qualitative assessment of fluorescent staining intensity for each relevant antigen was graded by visual inspection as negative, dim, or moderate/ bright based on the degree of overlap in the staining intensity for each relevant antigen in the plasma cell population compared with the corresponding antigen-negative reference normal population in the sample. 21 Of note, all samples were blocked with high concentration (30%-50%) of fetal bovine serum or normal mouse serum to suppress nonspecific binding. Mature granulocytes were used as negative controls for CD56 and CD52. T cells and granulocytes were used as negative controls for CD20. Negative antibody staining was defined as demonstration of approximately equivalent fluorescent staining intensity, generally, less than a 2-fold difference in geometric mean intensity, of the relevant antigen staining in the plasma cells compared with the geometric mean for the same antigen in the negative reference population within the same tube. Dim antibody staining was defined as greater intensity of the relevant antigen in the plasma cells than in the negative reference population, but with significant overlap of the intensity distributions, generally representing a 2- to 5-fold difference in geometric mean intensity. Moderate to bright positive staining showed minimal or no overlap in the distribution of intensities for the relevant antigen in the plasma cells and appropriate negative reference and represented a more than 5-fold increase in geometric mean intensity of the relevant antigen staining in the plasma cells as compared with the geometric mean intensity of the negative reference within the same tube. Immunophenotypic change was scored only when antigen staining intensity changed from negative to positive, regardless of relative intensity, or vice versa. Morphologic Features Peripheral blood smears, bone marrow aspirates, touch preparations, and bone marrow core biopsy specimens were reviewed. Plasma cell morphologic features and extent of bone marrow involvement were correlated with flow cytometric findings in all 56 cases. Statistical Analyses Statistical analyses were done by using GraphPad Prism software (San Diego, CA). The Fisher exact test, χ 2 test, and Mann-Whitney test were used for comparing nominal variables. The Student t test was used for comparing continuous variables between the 2 groups. A P value of less than.05 was considered significant. A CD45 APC-Cy7 C Cyto κ FITC Results Cyto λ PE CD56 PE-Cy7 Clinical and Pathologic Characteristics Of the 56 patients in this study, 38 were men and 18 were women with a median age of 60 years (range, years) when first encountered at Northwestern Memorial Hospital. The initial stages were as follows: stage I, 11; stage II, 10; and stage III, 35 ztable 1z. The follow-up interval ranged from 2 to 38 months (median, 7 months). Clinical management for each patient was different and included no treatment in 5 (9%); chemotherapy only (with 1 of the following: dexamethasone; vincristine, doxorubicin [Adriamycin], and dexamethasone combination; thalidomide; lenalidomide; or bortezomib) in 12 (21%); or combined chemotherapy and stem cell transplantation (autologous or, rarely, allogeneic) in 39 (70%). Flow Cytometric Findings The baseline immunophenotype in the 56 cases was as follows: κ+, 41 (73%); λ+, 15 (27%); CD56+, 41 (73%); CD45 APC-Cy7 CD138 PerCP-Cy5-5 CD138 PerCP-Cy5-5 zimage 1z Selection of malignant plasma cell population. A and B, Gated on bright CD38+ and/or CD138+, dim CD45+ to CD45 population. C, Selected plasma cells were cytoplasmic (cyto) κ or λ immunoglobulin light chain restricted. D, In a subset of patients coexpression of CD56 and CD38/ CD138 may be used to identify malignant plasma cells. APC, allophycocyanin; Cy, cyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin; PerCP, peridinin chlorophyll protein. B D 928 Am J Clin Pathol 2008;129: DOI: /8UVF7YQ1D4D4ETQV
4 Hematopathology / Original Article ztable 1z Clinical and Pathologic Characteristics According to Change in Immunophenotype * Immunophenotype Unstable Immunophenotype Total Stable Unstable CD56 CD20 CD52 (n = 56) (n = 33 [59%]) (n = 23 [41%]) P (n = 6) (n = 7) (n = 17) Sex M/F 38/18 22/11 16/7.89 6/0 4/3 12/5 Male (%) Median (range) age (y) 60 (38-79) 58 (38-77) 62 (47-79) (50-76) 58 (50-68) 64 (50-79) Monoclonal protein.007 IgA 12 (21) 3 (9) 9 (39) IgG 32 (57) 23 (70) 9 (39) Light chain only 11 (20) 7 (21) 4 (17) Nonsecretory 1 (2) 0 (0) 1 (4) Stage.17 I-II 21 (38) 15 (45) 6 (26) 0 (0) 4 (57) 4 (24) III 35 (63) 18 (55) 17 (74) 6 (100) 3 (43) 13 (76) Median (range) BM 16 (1-99) 10 (1-99) 20 (2-90) (1-75) 30 (4-90) 20 (1-99) involvement (%) Median (range) time between 7 (2-38) 12.5 (2-38) 6.5 (2-28) (3-33) 7 (3-28) 7.5 (2-28) analyses (mo) Therapy.52 No treatment 5 (9) 4 (12) 1 (4) Chemotherapy only 12 (21) 6 (18) 6 (26) Chemotherapy and SCT 39 (70) 23 (70) 16 (70) Response to therapy.99 Alive 47 (84) 28 (85) 19 (83) Died 9 (16) 5 (15) 4 (17) SCT, stem cell transplantation. * Data are given as number (percentage) unless otherwise indicated. P =.007 represents the significance between the IgA and IgG groups. P =.045 represents the significance between stable and unstable groups. CD20+, 15 (27%); and CD52+, 31 (55%). CD56 was positive in 41 of 56 cases; the majority of them (37/41 [90%]) were bright positive, 3 (7%) were dim positive, and 1 (2%) was partial positive. CD20 was expressed in 15 cases, of which 7 (47%) were bright positive and 8 (53%) were dim positive. CD52 showed a heterogeneous staining pattern in 31 cases: 10 (32%) were bright positive, 20 (65%) were dim positive, and 1 (3%) was partial positive. A change in immunophenotype was found in 23 (41%) of 56 cases. For individual antigens, CD56 changed in 6 cases (11%), including 4 cases that changed from CD56 to CD56+ and 2 cases that changed from CD56+ to CD56 zimage 2z. CD20 changed in 7 cases (13%), including 1 case from negative to dim positive and 5 cases from dim to negative; 1 case showed more variable CD20 staining (positive and negative) during follow-up (Image 2). CD52 changed in 17 cases (30%), including 5 cases changing from negative to positive, 9 from positive to negative, and 3 in which the staining pattern fluctuated between positive and negative multiple times zfigure 1z (Image 2). Furthermore, combined CD56/CD52 change was seen in 3 cases (1 case from CD56 /CD52+ to CD56+/CD52 ; 1 case from CD56+/ CD52 to CD56 /CD52+; and 1 case from CD56 /CD52 to CD56+/CD52+). Combined CD20/CD52 change was seen in 4 cases (3 cases from CD20+/CD52+ to CD20 / CD52 ; and 1 case from CD20 /CD52 to CD20+/CD52+). No change in κ or λ cytoplasmic immunoglobulin light chain was identified in any of the cases. In the 56 cases, 12 cases were evaluated only by 4-color, 13 cases only by 6-color, and 31 cases (55%) by 4- and 6-color methods. The frequency of antigenic change was similar in cases analyzed by 4-color, 6-color, and 4- and 6-color methods (7 [58%], 7 [54%], and 16 [52%], respectively). In the 31 cases studied by 4- and 6-color flow cytometry, 22 (71%) showed a stable antigen profile across the 4- to 6-color transition in method. Morphologic Findings In our series, the percentage of plasma cells obtained from flow cytometric analysis (0.1%-60%) differed in most cases from the percentage obtained from the bone marrow aspirate differential count. The difference ranged from essential agreement to 10% of the plasma cells seen morphologically. Therefore, the bone marrow aspirate differential count was used to evaluate the extent of marrow involvement. The overall extent of bone marrow involvement ranged from 1% to more than 99% and was similar in cases with a stable phenotype (1%-99%) and cases with an unstable phenotype Am J Clin Pathol 2008;129: DOI: /8UVF7YQ1D4D4ETQV 929
5 Cao et al / Instability o f Im m u n o p h e n o t y p e in PCM (2%-90%) zimage 3z. Within the cases showing antigenic change, the average extent of bone marrow involvement was similar regardless of antigen status (positive or negative, data not shown). Small plasma cells with lymphoplasmacytic morphologic features were present in 9 (60%) of 15 CD20+ cases, in agreement with recent reports. 22 None of the cases that changed CD20 immunophenotype exhibited significant corresponding plasma cell morphologic changes. In addition, no morphologic changes were seen in cases that changed CD56 or CD52 staining patterns. A CD56 PE-Cy7 B CD56 PE-Cy7 Immunophenotype Changes and Clinical and Pathologic Correlations Table 1 lists the patient clinical, pathologic, and immunophenotypic characteristics. The M components in the patients included IgA, IgG, light chain only, and nonsecretory. Of 12 patients with IgA, 9 (75%) showed antigenic change; only 9 (28%) of 32 patients with IgG showed a change (P =.0072). No statistically significant differences between patients with stable and changing antigen status were seen for age, sex, disease stage, time between analyses, and type of therapy or clinical response to therapy. However, the numbers of cases exhibiting antigenic shift for CD56, CD20, or CD52 are limited in this study, and some trends associated with antigenic shift are noted in the data in Table 1. Discussion Although antigenic shift has been well documented in hematopoietic disorders, including acute myeloid leukemia, 23 little information has been reported describing antigen stability in PCM. In this study, we documented changes in the immunophenotype of the plasma cells in more than 40% of patients during a 2- to 38-month follow-up. For the markers studied, the antigens that exhibited change in PCM were CD56, CD20, and CD52; the antigens that were stable were CD38, CD138, κ, and λ. In our studies, the neoplastic plasma cells were strongly CD38+ in all cases (100%); all cases but 1 (98%) were CD138+; and all showed dim CD45+ to CD45 staining (Image 1). The bright CD38+/bright CD45+ population, if present, was evaluated separately for clonality, but no cases showed cytoplasmic immunoglobulin light chain restriction (data not shown). Antigen frequencies of CD56 and cytoplasmic κ and λ were 73%, 73%, and 27% respectively, similar to previous reports. 8,9 We had slightly higher expression frequencies of CD20 (27%) and CD52 (55%) in our series than some previous studies, 9,17,22 but the frequencies were similar to others. 14,17 The higher frequency seen compared with some studies could be due to differences in monoclonal C E CD20 PE-Cy7 CD52 FITC antibodies used in the different laboratories. In addition, differences in nonspecific blocking reagents might also lead to differences in resolution of dim positive populations. In this study, a relatively high concentration (30%-50%) of fetal bovine serum or normal mouse serum was used. A statistically significant association of immunophenotype change with IgA myeloma was seen in this study. Of 12 IgA myelomas, 9 (75%) showed immunophenotypic change and constituted 39% of the cases exhibiting antigenic shift. Of 32 IgG myeloma cases, 9 (28%) showed immunophenotype change. Studies have shown that patients with IgA myeloma have a shorter median overall survival than patients with IgG myeloma 24,25 ; and the difference in overall CD20 PE-Cy7 CD52 FITC zimage 2z Flow cytometric analyses showing changes in antigen expression in plasma cells from patients with plasma cell myeloma. A and B, CD56 from negative to positive. C and D, CD20 from negative to positive. E and F, CD52 from negative to positive. APC, allophycocyanin; Cy7, cyanin 7; FITC, fluorescein isothiocyanate; PE, phycoerythrin. D F 930 Am J Clin Pathol 2008;129: DOI: /8UVF7YQ1D4D4ETQV
6 Hematopathology / Original Article A Immunophenotype unstable, 41% B to + 4 cases, 7% + to 2 cases, 4% Immunophenotype stable, 59% CD56 stable 50 cases, 89% C + to 1 case, 2% to + 5 cases, 9% CD20 stable 49 cases, 88% Multiple changes 1 case, 2% survival has been attributed to a shorter duration of plateau phase for patients with IgA myeloma compared with patients with IgG myeloma. 24 Recent studies showed that patients with PCM with t(4;14) had a predominance of IgA isotype (52%), and, although initial sensitivity to chemotherapy was shown, rapid relapse occurred. 26 Whether there is a relationship between the immunophenotypic instability of IgA myeloma and shortened survival is unclear. Of 56 cases, 6 (11%) showed CD56 change. Too few cases were available for statistical analysis; however, CD56 change seemed to be associated with higher stages of disease (all cases were stage III). Some authors have used CD19 and CD56 coupled with CD38, CD45, and CD138 to distinguish between normal and abnormal plasma cells, 27,28 and others have followed phenotype aberrations identified at diagnosis to monitor residual disease. 29 The results of this study raise the possibility of missing the disease when the phenotype changes and imply that these approaches should be used with caution. A panel of CD45 together with CD38, CD138, and cytoplasmic κ and λ staining may be a more effective way to detect residual disease. Nevertheless, inclusion of + to 9 cases, 16% to + 5 cases, 9% Multiple changes 3 cases, 5% CD52 stable 39 cases, 70% zfigure 1z Overall (A) and individual CD56 (B), CD20 (C), and CD52 (D) immunophenotype changes in 56 patients with plasma cell myeloma patients: stable vs unstable. D other antigens such as CD56 can be highly effective for detecting abnormal cells in a mixture of normal and abnormal plasma cells seen after therapy. A change in CD20 was seen in 13% of cases and in CD52 in 30% of cases. Loss of CD20 or CD52 antigen expression following immunotherapy with rituximab or alemtuzumab is common. 12,30,31 It is interesting that none of our patients were treated with rituximab or alemtuzumab during the follow-up period, and thus, these antigenic changes are not due to binding by therapeutic antibody to the assessed antigen. However, modulation of the antigen or antigenic deletion in response to other therapeutic approaches cannot be ruled out. Likewise, selective loss or, conversely, selective advantage of population subsets reflected in the immunophenotypic changes may have or is likely to be having a role. Recognition of antigen instability is important when considering antibody-based immunotherapy, at least with rituximab and alemtuzumab. Furthermore, antigen instability needs to be considered when monitoring disease in PCM. Am J Clin Pathol 2008;129: DOI: /8UVF7YQ1D4D4ETQV 931
7 Cao et al / Instability of Immunophenotype in PCM B C D zimage 3z Extent of bone marrow involvement and plasma cell morphologic features. A and B, Bone marrow involvement of 80% with mature plasma cell morphologic features (A, H&E, 40; B, Wright-Giemsa, 1,000). C and D, Focal bone marrow involvement and plasma cells with prominent nucleoli (C, H&E, 400; D, Wright-Giemsa, 1,000). From the Departments of 1Pathology and 2Medicine, Northwestern Memorial Hospital, Feinberg School of Medicine, Northwestern University, Chicago, IL. Address correspondence to Dr Peterson: Dept of Pathology, 251 E Huron St, Feinberg 7-205, Northwestern Memorial Hospital, Chicago, IL References 1. Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001: World Health Organization Classification of Tumours. 2. Goolsby CL, Paniagua M, Marszalek L. Clinical flow cytometry: a transition in utilization. Cancer Treat Res. 2004;121: Am J Clin Pathol 2008;129: DOI: /8UVF7YQ1D4D4ETQV 3. Kobayashi S, Hyo R, Amitani Y, et al. Four-color flow cytometric analysis of myeloma plasma cells. Am J Clin Pathol. 2006;126: Bataille R, Jego G, Robillard N, et al. The phenotype of normal, reactive and malignant plasma cells: identification of many and multiple myelomas and of new targets for myeloma therapy. Haematologica. 2006;91: Cruse JM, Lewis RE, Webb RN, et al. Antigenic transformation in plasma cell dyscrasia. Exp Mol Pathol. 2006;81: San Miguel JF, Gutierrez NC, Mateo G, et al. Conventional diagnostics in multiple myeloma. Eur J Cancer. 2006;42: Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res. 2005;11: A
8 Hematopathology / Original Article 8. Chang H, Samiee S, Yi QL. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leuk Lymphoma. 2006;47: Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121: Barille-Nion S, Barlogie B, Bataille R, et al. Advances in biology and therapy of multiple myeloma. Hematology Am Soc Hematol Educ Program. 2003: Pangalis GA, Kyrtsonis MC, Vassilakopoulos TP, et al. Immunotherapeutic and immunoregulatory drugs in haematologic malignancies. Curr Top Med Chem. 2006;6: Seliem RM, Freeman JK, Steingart RH, et al. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab. Appl Immunohistochem Mol Morphol. 2006;14: Moreau P, Voillat L, Benboukher L, et al. Rituximab in CD20 positive multiple myeloma [letter]. Leukemia. 2007;21: Treon SP, Pilarski LM, Belch AR, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother. 2002;25: Zojer N, Kirchbacher K, Vesely M, et al. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk Lymphoma. 2006;47: Rodig SJ, Abramson JS, Pinkus GS, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res. 2006;12: Kumar S, Kimlinger TK, Lust JA, et al. Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood. 2003;102: Carlo-Stella C, Guidetti A, Di Nicola M, et al. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. Exp Hematol. 2006;34: Rawstron A, Barrans S, Blythe D, et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol. 1999;104: Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36: Monaghan SA, Peterson LC, James C, et al. Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL). Cytometry B Clin Cytom. 2003;56: Robillard N, Avet-Loiseau H, Garand R, et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood. 2003;102: Voskova D, Schoch C, Schnittger S, et al. Stability of leukemiaassociated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry B Clin Cytom. 2004;62: Drayson M, Begum G, Basu S, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventionaldose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood. 2006;108: Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23: Jaksic W, Trudel S, Chang H, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol. 2005;23: Kara IO, Sahin B, Paydas S, et al. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients. Saudi Med J. 2004;25: Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood. 2002;100: Sarasquete ME, Garcia-Sanz R, Gonzalez D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90: Birhiray RE, Shaw G, Guldan S, et al. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H. Leukemia. 2002;16: Foran JM, Norton AJ, Micallef IN, et al. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-cd20): a retrospective cohort analysis. Br J Haematol. 2001;114: Am J Clin Pathol 2008;129: DOI: /8UVF7YQ1D4D4ETQV 933
Single Tube, Six-Color Flow Cytometric Analysis Is a Sensitive and Cost-Effective Technique for Assaying Clonal Plasma Cells
Hematopathology / Flow Cytometric Analysis of Clonal Plasma Cells Single Tube, Six-Color Flow Cytometric Analysis Is a Sensitive and Cost-Effective Technique for Assaying Clonal Plasma Cells Derek K. Marsee,
More informationImmunophenotyping of Peripheral Blood and Bone Marrow Cells by Flow Cytometry *Akanni EO and # Palini A.
Immunophenotyping of Peripheral Blood and Bone Marrow Cells by Flow Cytometry *Akanni EO and # Palini A. * Department of Haematology & Blood Transfusion,College of Health Science, Ladoke Akintola University
More informationFlow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma
Hematopathology / PLASMA CELL IMMUNOPHENOTYPING Flow Cytometric Immunophenotypic Analysis of 36 Cases of Multiple Myeloma Pei Lin, MD, 1* Rebecca Owens, 1 Guido Tricot, MD, PhD, 2 and Carla S. Wilson,
More informationThe diagnosis and classification of plasma cell dyscrasias
Quantitation of Plasma Cells in Bone Marrow Aspirates by Flow Cytometric Analysis Compared With Morphologic Assessment Kristi J. Smock, MD; Sherrie L. Perkins, MD, PhD; David W. Bahler, MD, PhD Context.
More informationFlow Cytometry in the Diagnosis of Hematopoietic Neoplasia. Brent Wood MD, PhD Professor, Laboratory Medicine University of Washington, Seattle
Flow Cytometry in the Diagnosis of Hematopoietic Neoplasia Brent Wood MD, PhD Professor, Laboratory Medicine University of Washington, Seattle 1 Flow Cytometer 2 The Power of Flow Cytometry Single cell
More informationProposals of B cells standard immunophenotyping in mature B cell non-hodgkin lymphomas
Clinical immunology Proposals of B cells standard immunophenotyping in mature B cell non-hodgkin lymphomas URSZULA PODSTAWKA, IZABELLA SZCZEPAŃSKA, JOANNA KOPEĆ-SZLĘZAK Department of Hematological Cytobiology,
More informationStandardization of Minimal Residual Disease Testing in Multiple Myeloma
Standardization of Minimal Residual Disease Testing in Multiple Myeloma Linda B. Baughn 1 and Michael A. Linden 2 * Multiple myeloma (MM) 3 is an incurable neoplasm of the bone marrow characterized by
More informationBIMM18 Dec 20 th - Flow cytometry in clinical diagnostics
BIMM18 Dec 20 th - Flow cytometry in clinical diagnostics I. B cell leukemia and lymphomas Immunophenotyping as part of the diagnostic work- up of hematologic malignancies offers a rapid and effective
More informationJune Laboratory Evaluation of Plasma Cell Neoplasms Stan McCormick, MD
June 2011 Laboratory Evaluation of Plasma Cell Neoplasms Stan McCormick, MD In this issue we review the laboratory work up of patients suspected of having a plasma cell neoplasm. As the range in clinical
More informationQuantification of Surface Antigens and Quantitative Flow Cytometry
5 Quantification of Surface Antigens and Quantitative Flow Cytometry Huai En Huang Chan, Iman Jilani, Richard Chang, and Maher Albitar Summary Measuring expression levels of cell surface antigens is important
More informationGuidelines for the diagnosis of Multiple Myeloma Ass.lec.: Dr. Karam T. Agha M.Sc.Pathology
Guidelines for the diagnosis of Multiple Myeloma 2014 By:British Committee for Standards in Haematology (BCSH) Ass.lec.: Dr. Karam T. Agha M.Sc.Pathology Diagnosis, prognostic factors and disease monitoring
More informationHigh-dimensional flow-cytometric analysis of human B-cell populations
High-dimensional flow-cytometric analysis of human B-cell populations The BD FACSCelesta cell analyzer and FlowJo software together enable deep analysis of B-cell biology Features High-resolution analysis
More informationAn approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/ lambda ratios of CD38-gated CD138 + cells
Nakayama et al. Diagnostic Pathology 2012, 7:131 RESEARCH Open Access An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/ lambda ratios of CD38-gated CD138 + cells
More information2111: ALL Post-HCT. Add/ Remove/ Modify. Manual Section. Date. Description. Comprehensive Disease- Specific Manuals
2111: ALL Post-HCT The Acute Lymphoblastic Leukemia Post-HCT Data Form is one of the Comprehensive Report Forms. This form captures ALL-specific post-hct data such as: planned treatments post-hct, the
More informationINTENDED PURPOSE. TECHNICAL SUMMARY.
Product: FITC Anti-Human CD2 Cat. Ref: 2F-100T Reagent provided: 100 test (20μl/test) Description: Mouse Monoclonal Anti-Human CD2 FITC is recommended for use in flow cytometry for identification of peripheral
More informationبسم اهلل الرمحن الرحيم
بسم اهلل الرمحن الرحيم Definition Multiple myeloma is a neoplastic plasma cell dyscrasia (PCD) that generally produced a monoclonal immunoglobulin protein, characterized by a clinical pentad: (a) anemia;
More informationRuud Hulspas, Mike Keeney, Ben Hedley and Andrea Illingworth
Sponsored and reviewed by ICCS Quality and Standards Committee Title: Quality of Reagents Monoclonal Antibodies Written by: Date: March 6, 2018 Ruud Hulspas, Mike Keeney, Ben Hedley and Andrea Illingworth
More informationThe NIAID Flow Cytometry Advisory Committee; the Guidelines Subcommittee
January, 1999 From: To: Subject: The NIAID Flow Cytometry Advisory Committee; the Guidelines Subcommittee NIAID DAIDS Flow Cytometry Laboratories Comparison study information for labs wishing to switch
More informationDiagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory
Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc. Learning Objectives Compare traditional
More informationDiagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory
Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc. Learning Objectives Compare traditional
More informationMinimum Information about a Flow Cytometry Experiment (MIFlowCyt) Annotation
Minimum Information about a Flow Cytometry Experiment (MIFlowCyt) Annotation 1. Experiment Overview 1.1 Purpose The purpose of these sets of experiments is to develop a methodology of identifying and quantifying
More informationThe analysis of L-selectin expression intensity (CD62L) on B-lymphocytes in B-cell chronic lymphocytic leukemia cells (B-CLL)
Experimental immunology The analysis of L-selectin expression intensity (CD62L) on B-lymphocytes in B-cell chronic lymphocytic leukemia cells (B-CLL) JOANNA KOPEÆ-SZLÊZAK 1, URSZULA PODSTAWKA 1, LECH KONOPKA
More informationStem Cells and Multiple Myeloma
Stem Cells and Multiple Myeloma What is Multiple Myeloma Multiple Myeloma is a cancer of your plasma cells, a type of white blood cell present in your bone marrow Plasma cells normally make proteins called
More informationDesigning and Implementing a High-Level Multicolor Flow Cytometry Assay. Brent Wood MD PhD Department of Laboratory Medicine University of Washington
Designing and Implementing a High-Level Multicolor Flow Cytometry Assay Brent Wood MD PhD Department of Laboratory Medicine University of Washington Define Purpose of Assay Most important question What
More informationSerum heavy-light chain analysis (Hevylite): clinical applications for multiple myeloma
Serum heavy-light chain analysis (Hevylite): clinical applications for multiple myeloma Kelly Endean PhD Scientific Affairs Manager, The Binding Site Focus of this talk An introduction to heavy-light chain
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation in the Era of Novel Therapies Larry Anderson, MD, PhD Multiple Myeloma and Stem Cell Transplant
More informationRef: CYT-MM-MRD. For Research Use Only. Not for use in diagnostic procedures
Ref: CYT-MM-MRD For Research Use Only. Not for use in diagnostic procedures MM MRD VIALS AND COMPENSATION TUBES ARE LYOPHILIZED PRODUCTS. READ CAREFULLY THE FOLLOWING INSTRUCTIONS FOR RECONSTITUTION: The
More informationApplication Note. Assay Portability on the BD FACSVerse System. Summary. Maria Jaimes, Yibing Wang, Catherine McIntyre, and Dev Mittar
September Assay Portability on the BD FACSVerse System Maria Jaimes, Yibing Wang, Catherine McIntyre, and Dev Mittar Contents Summary Introduction 3 Objective 4 Methods 6 Results Discussion Conclusions
More informationBD IMag. Streptavidin Particles Plus - DM. Technical Data Sheet. Product Information
Technical Data Sheet Streptavidin Particles Plus - DM Product Information Material Number: Size: Storage Buffer: 557812 5 ml Aqueous buffered solution containing BSA and 0.09% sodium azide. Description
More informationStrategies for Assessment of Immunotoxicology in Preclinical Drug Development
Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects
More informationManaging Specimen Stability for Robust Flow Cytometric Clinical Biomarker Assays
Managing Specimen Stability for Robust Flow Cytometric Clinical Biomarker Assays Dianna Wu, Richard Wnek Molecular Biomarkers & Diagnostics Merck Co., Inc 2014 AAPS Annual Meeting San Diego, CA (Fluorescent
More informationFlow cytometry has become an increasingly important
9-Color and 10-Color Flow Cytometry in the Clinical Laboratory Brent Wood, MD, PhD Context. The development of commercial flow cytometers capable of detecting more than 10 simultaneous fluorescent signals
More informationMultiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA
Multiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA July 13, 2015 Welcome and Introductions Anne Quinn Young, MPH Multiple Myeloma Research Foundation Norwalk, CT
More informationBringing the EuroFlow Concept
Bringing the EuroFlow Concept Cytognos - EuroFlow Supporting Company Company Overview Cytognos provides through worldwide distribution a broad range of reagents and software for flow cytometry applications
More informationSUBCLASSIFICATION OF ACUTE MYELOGENOUS LEUKEMIA PATIENTS BASED ON CHEMOKINE RESPONSIVENESS AND CONSTITUTIVE CHEMOKINE RELEASE BY
Supplementary Appendix SUBCLASSIFICATION OF ACUTE MYELOGENOUS LEUKEMIA PATIENTS BASED ON CHEMOKINE RESPONSIVENESS AND CONSTITUTIVE CHEMOKINE RELEASE BY THE LEUKEMIA CELLS Øystein Bruserud 1, Anita Ryningen
More informationCellular phenotyping and application of cytometry for diagnostics purposes Part I. dr n. med. Karolina Bukowska-Straková
Cellular phenotyping and application of cytometry for diagnostics purposes Part I dr n. med. Karolina Bukowska-Straková Flow cytometry - wikipedia definition ;-) Flow cytometry (abbreviated: FCM) is a
More informationIn vivo BrdU Incorporation Assay for Murine Hematopioetic Stem Cells Ningfei An, Yubin Kang *
In vivo BrdU Incorporation Assay for Murine Hematopioetic Stem Cells Ningfei An, Yubin Kang * Division of Hematology-Oncology, Department of Medicine, Medical University of South Carolina, Charleston,
More informationValidation of reagents and mixes in haematology. Tine Venken
Validation of reagents and mixes in haematology Tine Venken Molecular Biology and Cytometry Course 23-24/03/2017 Overview ISO 15189:2012 Validation of reagents Validation of mixes Daily practice Conclusions
More informationTechnical Note: A Counting Strategy for Estimating Plasma Cell Number in CD138-Stained Bone Marrow Core Biopsy Sections
Available online at www.annclinlabsci.org 138 Technical Note: A Counting Strategy for Estimating Plasma Cell Number in CD138-Stained Bone Marrow Core Biopsy Sections Fred B. Smith and Ashraf Elnawawi Department
More informationCongreso Nacional del Laboratorio Clínico 2016
Técnicas de alta sensibilidad en la detección de enfermedad mínima residual en Mieloma Múltiple J. Flores-Montero, MD, PhD Departamento de Medicina, Servicio Central de Citometría, Centro de Investigación
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Transformed Pre- Ig Surface Surface Secreted B- ALL Macroglobulinemia Myeloma
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationCLEARLLAB LS LYMPHOID SCREEN REAGENT
CLEARLLAB LS LYMPHOID SCREEN REAGENT CE MARKED ANTIBODY COMBINATION FOR LEUKEMIA / LYMPHOMA ANALYSIS Because Your Patient is Her Everything BECAUSE YOUR PATIENT IS HER EVERYTHING ClearLLab LS Lymphoid
More informationHot Topic. Disclosures. None
Hot Topic Multiple Myeloma Testing at Mayo Medical Laboratories HOT TOPIC / 2017 MFMER 1 Our speaker for this program is Dragan Jevremovic, MD, PhD Assistant Professor, Division of Hematopathology at Mayo
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pr e- Transformed Ig Su rf ace Su rf ace Secre ted Myelom a
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pr e- B-ce ll B-ce ll Transformed B-ce ll Plasma cell Ig Su rf ace Su rf ace Secre ted Major malignant
More informationTreatment options in Myeloma. BritModis myeloma for the elderly care specialist
Treatment options in Myeloma myeloma for the elderly care specialist Dr Richard Soutar, Consultant in Haematology and Transfusion Medicine, Beatson Oncology Centre, Glasgow and The Scottish National Blood
More informationINTERNATIONAL SOCIETY OF LABORATORY HEMATOLOGY. 30TH INTERNATIONAL SYMPOSIUM May, 2017 / HONOLULU, HAWAII
INTERNATIONAL SOCIETY OF LABORATORY HEMATOLOGY 30TH INTERNATIONAL SYMPOSIUM 04-06 May, 2017 / HONOLULU, HAWAII Michael Keeney, ART, FCSMLS(D) Coordinator Special Hematology, London Health Sciences Centre,
More informationCME/SAM. Limited Flow Cytometry Panels on Bone Marrow Specimens Reduce Costs and Predict Negative Cytogenetics
Limited Flow Cytometry Panels on Bone Marrow Specimens Reduce Costs and Predict Negative Cytogenetics Douglas G. Hoffmann, MD, and Burton H. Kim, MD From the Department of Pathology, Wellstar Health System,
More informationThe histopathology of myeloma in the bone marrow
Journal of clinical and experimental hematopathology Vol. 58 No.2, 61-67, 2018 JC lin EH xp ematopathol Review Article The histopathology of myeloma in the bone marrow Masahiko Fujino Myeloma is characterized
More informationMinimal Residual Disease assessment in Multiple Myeloma by Next-Generation Sequencing
Minimal Residual Disease assessment in Multiple Myeloma by Next-Generation Sequencing Prof Hervé AVET-LOISEAU, : MD, PhD Institut Universitaire du Cancer Toulouse, France MRD Meta-Analysis in Myeloma Nikhil
More informationA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma Paul G. Richardson, M.D., Bart Barlogie, M.D., Ph.D., James Berenson, M.D., Seema Singhal, M.D., Sundar Jagannath, M.D., David Irwin, M.D.,
More informationIncorporating New, Bright Fluorochromes into Multicolor Panel Design
Incorporating New, Bright Fluorochromes into Multicolor Panel Design Maria C. Jaimes, MD Senior Staff Scientist BD Biosciences 23-14684-00 Overview Multicolor flow: successful application prerequisites
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus
More informationParameswaran Hari Medical College of Wisconsin Milwaukee
Multiple Myeloma Linking the clinical course to report forms Parameswaran Hari Medical College of Wisconsin Milwaukee 45,000 Annual Numbers of Blood and Marrow Transplants Worldwide 1970-2003 40,000 Number
More informationFlow Cytometry - The Essentials
Flow Cytometry - The Essentials Pocket Guide to Flow Cytometry: 1. Know your Cytometer 2. Understanding Fluorescence and Fluorophores 3. Gating Process 4. Controls 5. Optimization 6. Panel Building 7.
More informationPrinciples of flow cytometry: overview of flow cytometry and its uses for cell analysis and sorting. Shoreline Community College BIOL 288
Principles of flow cytometry: overview of flow cytometry and its uses for cell analysis and sorting Shoreline Community College BIOL 288 Flow Cytometry What is Flow Cytometry? Measurement of cells or particles
More informationDARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512 Henk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Monique
More informationWhat do you do, with an M protein?
What do you do, with an M protein? Cancer Day for Primary Care Emily Rimmer MD FRCPC January 31, 2014 emily.rimmer@cancercare.mb.ca Disclosure of Potential for Conflict of Interest Name of presenter: Emily
More informationSelected Topics in Electrical Engineering: Flow Cytometry Data Analysis
Selected Topics in Electrical Engineering: Flow Cytometry Data Analysis Bilge Karaçalı, PhD Department of Electrical and Electronics Engineering Izmir Institute of Technology Outline Experimental design
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Dr Guy Pratt #MyelomaInfodays This talk will cover What is relapse and refractory myeloma Treatment options for relapse Treatment options for refractory
More informationIdentification of red and white blood cells from whole blood samples using the Agilent 2100 bioanalyzer. Application Note
Identification of red and white blood cells from whole blood samples using the Agilent 2100 bioanalyzer Application Note Sylvie Veriac Valérie Perrone Madeleine Avon Abstract Agilent Equipment: 2100 bioanalyzer
More informationAPC Anti-Human FoxP3 Transcription Factor Staining
APC Anti-Human FoxP3 Transcription Factor Staining Catalog Kit Number: 20-4770-KIT Kit Components APC Anti-Human Foxp3 with Isotype Control (TBhP3, TBhISO)... Cat.No. 20-4773- T025... Size 25 tests (Page
More informationBD Multicolor CompBeads
4/2015 23-9955-01 IVD BD Multicolor CompBeads 100 compensation setups Catalog No. 644204 BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. 2015 BD Becton, Dickinson and
More informationUrine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples
Immunopathology / Electrophoresis of Unconcentrated Urine Samples Urine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples Anja C. Roden, MD,
More informationClinical Policy: Lenalidomide (Revlimid) Reference Number: CP.CPA.275 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationMRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods
REGULAR ARTICLE MRD detection in multiple myeloma: comparison between MSKCC 1-color single-tube and EuroFlow 8-color 2-tube methods Mikhail Roshal, 1 Juan A. Flores-Montero, 2-4 Qi Gao, 1 Maesa Koeber,
More informationThis talk will cover. Treatment for relapsed and/or refractory myeloma. What is relapsed myeloma and refractory myeloma. Treatment options for relapse
This talk will cover Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist Heart of England NHS Trust and Senior Lecturer in Haematology University of Birmingham What is
More informationCFSE Cell Division Assay Kit
CFSE Cell Division Assay Kit Catalog Number KA1302 100 assays Version: 02 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 General Information...
More informationRestrooms Cell phones on silent/vibrate. Refreshments. Patient resource materials
Restrooms Cell phones on silent/vibrate Refreshments Patient resource materials This presentation should not replace discussions with your healthcare provider, but seeks to provide information and resources
More informationEDUCATIONAL COMMENTARY LABORATORY EVALUATION OF IMMUNOPROLIFERATIVE DISORDERS
Commentary provided by: Louann W. Lawrence, Dr.PH, MLS (ASCP) Professor Emeritus, Retired Louisiana State University Health Sciences Center New Orleans, LA EDUCATIONAL COMMENTARY LABORATORY EVALUATION
More informationISCT Telegraft Column: Mesenchymal Stromal Cell (MSC) Product Characterization and Potency Assay Development
ISCT Telegraft Column: Mesenchymal Stromal Cell (MSC) Product Characterization and Potency Assay Development University of Wisconsin-Madison, Production Assistance for Cellular Therapies (PACT) Over the
More informationTitration of Fluorochrome-Conjugated Antibodies for Labeling Cell Surface Markers on Live Cells
Titration of Fluorochrome-Conjugated Antibodies for Labeling Cell Surface Markers on Live Cells Ruud Hulspas 1 UNIT 6.29 1 Cytonome/ST, Boston, Massachusetts ABSTRACT Nonspecific antibody binding is best
More informationMyeloma treatment algorithm 1999
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationacute leukemia precursor chronic leukemia lymphoma
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated t d Pre- B-cell B-cell Ig Surface Transformed B-cell Surface Plasma cell Secreted Major malignant counterpart
More informationab pdc Subset Phenotyping Kit
ab177772 pdc Subset Phenotyping Kit Instructions for Use A set of antibodies designed to identify pdcs and subsets of pdcs by multi-color flow cytometry. This product is for research use only and is not
More informationA high recovery and high purity data analysis strategy for rare abnormal plasma cell events using the DuraClone RE PC Tube
APPLICATION NOTE A high recovery and high purity data analysis strategy for rare abnormal plasma cell events using the DuraClone RE PC Tube Dr Agnieszka Blum Charité Virchow Hospital, Stem Cell Facility,
More informationImmunophenotyping UNIT
Immunophenotyping UNIT 6.2 There are four basic methods for staining cells with antibodies for immunophenotyping by flow cytometry. The first method (see Basic Protocol 1) is an indirect one that employs
More informationAnti-Lambda ( )
Anti-Lambda (1-155-2) Monoclonal mouse anti-human reagent for identification of cells expressing lambda light chains 10/2013 23-5590-03 IVD Form Catalog No. FITC 347247 PE 642925 Not for sale in the US
More informationLaboratory Persistence and Clinical Progression of Small Monoclonal Abnormalities
Immunopathology / Persistence of IFE MGUS Laboratory Persistence and Clinical Progression of Small Monoclonal Abnormalities David L. Murray, MD, PhD, 1 Justin L. Seningen, MD, 1 Angela Dispenzieri, MD,
More informationAmendment to ALL IC-BFM 2009 Standard Operating Procedure. 6-color FLOW-MRD detection in ALL
Amendment to ALL IC-BFM 2009 Standard Operating Procedure 6-color FLOW-MRD detection in ALL Version June 2014 M.N. Dworzak/J. Kappelmayer ALL IC-BFM 2009 FLOW-MRD SOP amendment June 2014 page 1 Marker
More informationa Beckman Coulter Life Sciences: White Paper
a Beckman Coulter Life Sciences: White Paper Flow Cytometric Analysis of Endothelial Progenitor Cells Authors: Affiliation: Dorota Sadowicz, Vasilis Toxavidis, John Tigges Beth Israel Deaconess Medical
More informationCitation for published version (APA): Hovenga, S. (2007). Clinical and biological aspects of Multiple Myeloma s.n.
University of Groningen Clinical and biological aspects of Multiple Myeloma Hovenga, Sjoerd IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationCD22 (S-HCL-1) IVD. Table 1 Bottling concentrations. Monoclonal mouse anti-human reagent for identification of cells expressing CD22 antigen
2/2014 23-6995-02 IVD CD22 (S-HCL-1) Monoclonal mouse anti-human reagent for identification of cells expressing CD22 antigen Form Catalog No. FITC 337898 PE 337899 APC 333145 BD, BD Logo and all other
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationLABORATORY ASSESSMENT OF HAEMATOLOGY ONCOLOGY IMMUNOPHENOTYPING. First Edition Australasian Cytometry Society Laboratory Assessment Document
LABORATORY ASSESSMENT OF HAEMATOLOGY ONCOLOGY IMMUNOPHENOTYPING First Edition 2018 Australasian Cytometry Society Laboratory Assessment Document Paper-based publications This work is copyright. You may
More informationCytomics in Action: Cytokine Network Cytometry
Cytomics in Action: Cytokine Network Cytometry Jonni S. Moore, Ph.D. Director, Clinical and Research Flow Cytometry and PathBioResource Associate Professor of Pathology & Laboratory Medicine University
More informationDARATUMUMAB HARD TO PRONOUNCE - EVEN HARDER ON BLOOD BANK TESTING. Dr. Jennifer Duncan Hematopathology Resident March 18, 2017
DARATUMUMAB HARD TO PRONOUNCE - EVEN HARDER ON BLOOD BANK TESTING Dr. Jennifer Duncan Hematopathology Resident March 18, 2017 Goals and Objectives: Briefly describe the use of dara in the treatment of
More informationTherapeutic monoclonal antibodies & blood transfusion Essential information for hospital transfusion laboratories, transfusion practitioners &
Therapeutic monoclonal antibodies & blood transfusion Essential information for hospital transfusion laboratories, transfusion practitioners & haematology clinical teams March 2018 Background Targeted
More informationElevated Immunoglobulins and Paraproteins
Elevated Immunoglobulins and Paraproteins NWL Pathology GP Study Afternoon Thursday 19 th October 2017 Dr Aristeidis Chaidos Consultant Haematologist and Honorary Senior Clinical Lecturer Hammersmith Hospital,
More informationA Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
1 von 5 10.12.2013 10:33 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: MOR202C101 Previous Study Return to List Next Study A Phase I/IIa Study of Human Anti-CD38 Antibody
More informationDetection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma
Wang et al. BMC Cancer (2018) 18:650 https://doi.org/10.1186/s12885-018-4562-8 RESEARCH ARTICLE Open Access Detection of intracellular IgD using flow cytometry could be a novel and supplementary method
More informationSalvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
Salvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Arnon Nagler, M.D., M.Sc Director Hematology Division BMT and Cord Blood Bank Chair Israeli BMT Association Chaim Sheba Medical Center,
More informationFlow Cytometry Immune Activation SOP
Flow Cytometry Immune Activation SOP Purpose This SOP standardizes the procedure for measuring immune activation of T cells using flow cytometry in ACTG Immunology Laboratories. Materials 1. 12x75mm flow
More informationSupplemental Information Inventory
Cell Stem Cell, Volume 6 Supplemental Information Distinct Hematopoietic Stem Cell Subtypes Are Differentially Regulated by TGF-β1 Grant A. Challen, Nathan C. Boles, Stuart M. Chambers, and Margaret A.
More informationProduct datasheet. ARG30119 Pro-B Cell Marker Antibody panel (CD19, CD34, CD38, CD40, CD45)(FACS)
Product datasheet info@arigobio.com Package: 1 kit ARG30119 Pro-B Cell Marker Antibody panel (CD19, CD34, CD38, CD40, CD45)(FACS) Component Cat. No. Component Name ARG62820 anti-cd34 antibody [4H11(APG)]
More informationTitle Clinical Contribution of PET/CT in Perspective of a Radiologist. Author(s) Nakamoto, Yuji Citation Clinical lymphoma, myeloma & leukem Issue Date 2014-02 URL http://hdl.handle.net/2433/182042 Right
More informationBD IntraSure Kit IVD. Cell fixation and permeabilization reagents. 50 tests per kit Catalog No
03/2015 23-8992-01 IVD BD IntraSure Kit Cell fixation and permeabilization reagents 50 tests per kit Catalog No. 641778 BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company.
More informationHematopoietic Progenitor Cell Product Characterization
Hematopoietic Progenitor Cell Product Characterization Carolyn A. Taylor, Ph.D. Professor of Medicine Director of BMT Program Cell Processing Laboratory Product Testing and Characterization Goals Required
More informationPRINCIPLES OF THE PROCEDURE
CD19 For In Vitro Diagnostic use Fluorochrome Reference Clon Isotype Format µl/test FITC CYT-19F6 HIB19 IgG1 1 ml/200 test 5 PerCP-Cyanine5.5 CYT-19C8 HIB19 IgG1 150ul/50 test 3 PE-Cyanine5 CYT-19C3 HIB19
More informationEdU Click FC ROTI kit for Flow Cytometry
USER MANUAL EdU Click FC EdU Click FC Introduction and product description: The detection of cell proliferation is of utmost importance for assessing cell health, determining genotoxicity or evaluating
More informationFlow Cytometric Preparation of CD34 + CD90 + Hematopoietic Stem Cells for Transplantation
Flow Cytometric Preparation of CD34 + CD9 + Hematopoietic Stem Cells for Transplantation B R YA N F OX S TA N F O R D L A B O R AT O R Y F O R C ELL & G ENE M E D I C I N E ISCT Regional Meeting Memphis,TN
More information